论文部分内容阅读
目的研究BRCA1、ERCC1和EGFR在非小细胞肺癌(NSCLC)中的表达及预后意义。方法用免疫组化ElivisionTM plus法,检测77例非小细胞肺癌和6例癌旁组织中BRCA1、ERCC1和EGFR的表达情况。结果非小细肺癌中BRCA1、ERCC1、EGFR在癌中的表达显著高于癌旁组织,且在癌中的表达具有正相关性;BRCA1、ERCC1在不同病理类型和分期中表达均无差异;BRCA1高表达组的生存期明显小于低表达组;EGFR有淋巴结转移组阳性表达率明显高于无淋巴结转移组;应用铂类药物化疗ERCC1低表达组的生存期明显明显长于高表达组。结论在NSCLC中BRCA1、ERCC1、EGFR在肺癌中的表达显著高于癌旁组织,BRCA1高表达组的生存期明显小于低表达组,EGFR高表达可能促进肿瘤的侵袭和转移,ERCC1是铂类治疗独立的预后因素,三项抗体的检测与预后和临床用药密切相关。
Objective To study the expression and prognostic significance of BRCA1, ERCC1 and EGFR in non-small cell lung cancer (NSCLC). Methods The expressions of BRCA1, ERCC1 and EGFR in 77 non-small cell lung cancer and 6 paracancerous tissues were detected by immunohistochemistry ElivisionTM plus method. Results The expression of BRCA1, ERCC1 and EGFR in non-small benign lung cancer was significantly higher than that in adjacent non-small cell lung cancer and there was a positive correlation between the expression of BRCA1 and ERCC1 in different pathological types and stages. The expression of BRCA1 The survival time of high expression group was significantly less than that of low expression group. The positive expression rate of EGFR in lymph node metastasis group was significantly higher than that in non-lymph node metastasis group. The survival time of ERCC1 low expression group was significantly longer than that of high expression group. Conclusion The expression of BRCA1, ERCC1 and EGFR in NSCLC is significantly higher than that in paracancerous tissues. The survival of BRCA1 overexpression group is significantly lower than that in low expression group. The high expression of EGFR may promote the invasion and metastasis of tumor. ERCC1 is a platinum treatment Independent prognostic factors, the detection of three antibodies and prognosis and clinical use are closely related.